Genetic Testing in Retinoblastoma: New Applications

Liquid biopsy and molecular profiling are expanding the diagnostic and prognostic role of genetic testing in retinoblastoma.

Category	Detail
Condition	Retinoblastoma
Key Mechanisms	Genetic testing for germline mutations, liquid biopsy, cfDNA analysis, and tumor profiling.
Target Population	Children at risk for retinoblastoma, including those with hereditary forms.
Care Setting	Ophthalmology and oncology clinics.

Liquid biopsy and molecular profiling enhance diagnosis and prognosis in retinoblastoma.
Aqueous humor cfDNA analysis shows high sensitivity and specificity for active disease detection.
Genetic testing may guide targeted germline testing and improve diagnostic sensitivity.
Chromosomal alterations and ctDNA levels correlate with tumor aggressiveness and metastasis risk.
Emerging genetic testing strategies enable personalized management of retinoblastoma.

Utilize liquid biopsy for tumor genotyping to guide treatment decisions.
Consider genetic testing for prognostic information regarding local recurrence and metastasis.

Monitor ctDNA levels for correlation with ocular disease progression and treatment response.

False-negative results may occur in small tumors or those retaining an intact RB1 gene.

Children diagnosed with retinoblastoma, particularly those with hereditary risk factors.

Intra-arterial and intravitreal chemotherapy are preferred over primary enucleation in many cases.

Incorporate genetic testing in the diagnostic workup for retinoblastoma.
Educate families about the implications of genetic findings and potential risks.